EURL ECVAM indicators to assess the impact of EU-funded research into Alzheimer's Disease, Breast Cancer and Prostate Cancer

Biomedical research is extremely resource intensive. Therefore, monitoring its outputs and impacts can be considered a priority to gain an understanding of the most productive research avenues worth investing in.

For this reason, in 2019 the European Commission’s Joint Research Centre (JRC), through its European Union Reference Laboratory for alternatives to animal testing (EURL ECVAM), initiated a project to define suitable and reliable indicators to measure the innovation and impact of EU-funded research in three areas of biomedical research: Alzheimer’s disease, breast cancer and prostate cancer. These diseases are highly prevalent, representing a heavy societal and economic burden for Europe, and have attracted a large share of
the investments made through several Commission funding programmes.

A set of 14 indicators was built that cover different scientific and societal aspects. This dataset provides the main data used to select, refine and implement these indicators as described in the JRC report "Building indicators to assess the impact of EU-funded research into Alzheimer's disease, Brest cancer and Prostate cancer". This dataset can also be used to generate additional indicators and insight through an integrated analysis applied to the abovementioned biomedical research areas.